Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Jun;47(6):674-686.
doi: 10.1007/s00134-021-06431-0. Epub 2021 May 29.

Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial

Lore Vanderbeke #  1   2 , Nico A F Janssen #  3   4 , Dennis C J J Bergmans  5 , Marc Bourgeois  6 , Jochem B Buil  4   7 , Yves Debaveye  8   9 , Pieter Depuydt  10 , Simon Feys  1   2 , Greet Hermans  2   8 , Oscar Hoiting  11 , Ben van der Hoven  12 , Cato Jacobs  2 , Katrien Lagrou  1   13 , Virginie Lemiale  14 , Piet Lormans  15 , Johan Maertens  1   16 , Philippe Meersseman  1   2 , Bruno Mégarbane  17 , Saad Nseir  18 , Jos A H van Oers  19 , Marijke Reynders  20 , Bart J A Rijnders  21 , Jeroen A Schouten  22 , Isabel Spriet  23   24 , Karin Thevissen  25 , Arnaud W Thille  26 , Ruth Van Daele  23   24 , Frank L van de Veerdonk  3   4 , Paul E Verweij  4   7 , Alexander Wilmer  1   2 , Roger J M Brüggemann #  4   27 , Joost Wauters #  28   29 ; Dutch-Belgian Mycosis Study Group
Collaborators, Affiliations
Randomized Controlled Trial

Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial

Lore Vanderbeke et al. Intensive Care Med. 2021 Jun.

Abstract

Purpose: Influenza-associated pulmonary aspergillosis (IAPA) is a frequent complication in critically ill influenza patients, associated with significant mortality. We investigated whether antifungal prophylaxis reduces the incidence of IAPA.

Methods: We compared 7 days of intravenous posaconazole (POS) prophylaxis with no prophylaxis (standard-of-care only, SOC) in a randomised, open-label, proof-of-concept trial in patients admitted to an intensive care unit (ICU) with respiratory failure due to influenza (ClinicalTrials.gov, NCT03378479). Adult patients with PCR-confirmed influenza were block randomised (1:1) within 10 days of symptoms onset and 48 h of ICU admission. The primary endpoint was the incidence of IAPA during ICU stay in patients who did not have IAPA within 48 h of ICU admission (modified intention-to-treat (MITT) population).

Results: Eighty-eight critically ill influenza patients were randomly allocated to POS or SOC. IAPA occurred in 21 cases (24%), the majority of which (71%, 15/21) were diagnosed within 48 h of ICU admission, excluding them from the MITT population. The incidence of IAPA was not significantly reduced in the POS arm (5.4%, 2/37) compared with SOC (11.1%, 4/36; between-group difference 5.7%; 95% CI - 10.8 to 21.7; p = 0.32). ICU mortality of early IAPA was high (53%), despite rapid antifungal treatment.

Conclusion: The higher than expected incidence of early IAPA precludes any definite conclusion on POS prophylaxis. High mortality of early IAPA, despite timely antifungal therapy, indicates that alternative management strategies are required. After 48 h, still 11% of patients developed IAPA. As these could benefit from prophylaxis, differentiated strategies are likely needed to manage IAPA in the ICU.

Keywords: Aspergillosis; Critical illness; Influenza; Posaconazole; Prophylaxis.

PubMed Disclaimer

Conflict of interest statement

JBB reports grants from F2G, grants from Gilead Sciences, grants from Thermo Fisher Scientific, outside the submitted work. KL received consultancy fees from MSD, SMB Laboratoires Brussels and Gilead, non-financial support from Pfizer and MSD, received speaker fees from Gilead Sciences, FUJIFILM WAKO and Pfizer and a grant from Thermo Fisher Scientific. VL reports financial support of Pfizer, Fisher Paykel, Gilead Sciences, Alexion and Celgene to her research group, outside the submitted work. JM reports grants, personal fees and non-financial support from Gilead Sciences, MSD and Pfizer; personal fees and non-financial support from Cidara, F2G and Mundipharma; outside the submitted work. AWT reports personal fees and non-financial support from Fisher&Paykel, outside the submitted work. RVD reports non-financial support from Pfizer and Gilead Sciences, outside the submitted work. LV reports non-financial support from Gilead Sciences, outside the submitted work. PEV reports grants from Mundipharma, grants from F2G, grants from Pfizer, grants from Thermofisher, grants from Gilead Sciences, non-financial support from IMMY, grants from Cidara, outside the submitted work. RJMB reports consultancy fees from Mundipharma, Cidara, Amplyx, F2G, Gilead, Pfizer and MSD, speaker fees from Pfizer and Gilead, grants from Pfizer, Gilead and MSD. JW received speakers fee from MSD, Pfizer and Gilead, consultancy fee from Gilead and he obtained investigator-initiated grants from Gilead, Pfizer and MSD.

Figures

Fig. 1
Fig. 1
Trial profile. ICU intensive care unit, IAPA influenza-associated pulmonary aspergillosis, IPA invasive pulmonary aspergillosis, QTc corrected QT-interval
Fig. 2
Fig. 2
Time to influenza-associated pulmonary aspergillosis. Data derived from modified intention-to-treat population; at 90 days after intensive care admission all patient data were censored. IAPA diagnosis based on modified AspICU criteria. CI confidence interval, HR hazard ratio, IAPA influenza-associated pulmonary aspergillosis, ICU intensive care unit, N° number, POS posaconazole prophylaxis, SOC standard-of-care
See this image and copyright information in PMC

Comment in

References

    1. van de Veerdonk FL, Kolwijck E, Lestrade PPA, et al. Influenza-associated aspergillosis in critically ill patients. Am J Respir Crit Care Med. 2017;196:524–527. doi: 10.1164/rccm.201612-2540LE. - DOI - PubMed
    1. Schauwvlieghe AFAD, Rijnders BJA, Philips N, et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med. 2018;6:782–792. doi: 10.1016/S2213-2600(18)30274-1. - DOI - PubMed
    1. Chen L, Han X, Li Y, et al. Invasive pulmonary aspergillosis in immunocompetent patients hospitalised with influenza A-related pneumonia: a multicenter retrospective study. BMC Pulm Med. 2020;20:239. doi: 10.1186/s12890-020-01257-w. - DOI - PMC - PubMed
    1. Ku Y-H, Chan K-S, Yang C-C, et al. Higher mortality of severe influenza patients with probable aspergillosis than those with and without other coinfections. J Formos Med Assoc. 2017;116:660–670. doi: 10.1016/J.JFMA.2017.06.002. - DOI - PubMed
    1. Schwartz IS, Friedman DZP, Zapernick L, et al. High rates of influenza-associated invasive pulmonary aspergillosis may not be universal: a retrospective cohort study from alberta, canada. Clin Infect Dis. 2020;71:1760–1763. doi: 10.1093/cid/ciaa007. - DOI - PubMed

Publication types

MeSH terms

Associated data

LinkOut - more resources